目的 通过检索1994—2024年眼部药物警戒领域相关文献，并使用文献计量工具CiteSpace可视化，探析该领域的研究现状﹑热点﹑前沿和未来趋势。方法 以Web of Science（WOS）和中国学术期刊全文数据库（CNKI）﹑万方数据库（Wanfang Data）、维普数据库（VIP）等核心集数据库为数据源，使用CiteSpace软件对发文量趋势、国家、作者、机构、关键词的共现、聚类和突现情况进行可视化分析。结果 共纳入546篇有效文献，其中英文文献517篇，中文文献29篇，发文数量呈上升趋势。我国在眼部药物警戒域研究较少。这些研究来自60个国家，其中美国对该领域的贡献最大。来自142家机构的187名研究学者对眼部药物警戒进行了研究，诺华制药公司的文献贡献量最多，哈佛大学是该研究领域研究探索最多的大学。日本学者Aihara,Makoto发文量最高，美国学者Abelson,M B在该领域研究最早。结论 基于关键词共现分析，确定了3个研究主题：眼科药品临床试验﹑药品管理和治疗、免疫检查点抑制剂和抗体药物耦联物相关眼科不良反应和评估是该领域研究的前沿。药物不良事件和药品临床研究仍可能是未来研究的持续热点。

Objective This study searched for relevant literature in the field of ocular pharmacovigilance from 1994 to 2024 and used the bibliometric tool CiteSpace for visualization to explore the current research status, hotspots, frontiers and future trends in this field. Methods Using core set databases such as Web of Science (WOS), China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP as data sources, The CiteSpace software was used to conduct a visual analysis of the trends in the number of published articles, the co-occurrence, clustering and emergent situations of countries, authors, institutions and keywords. Results A total of 546 valid publications were included in this study, among which 517 were in English and 29 were in Chinese. The number of published articles shows an upward trend. There are relatively few studies in the field of ocular pharmacovigilance in our country. These studies come from 60 countries, among which the United States has made the greatest contribution to this field. A total of 187 research scholars from 142 institutions conducted studies on ocular pharmacovigilance. Novartis Pharmaceuticals contributed the most literature, and Harvard University was the university that explored the most in this research field. The Japanese scholars Aihara, Makoto have published the most papers, while the American scholar Abelson, MB have been the earliest to conduct research in this field. Conclusion Based on the co-occurrence analysis of keywords, this study identified three research topics: Clinical trials of ophthalmic drugs, drug management and treatment. Ophthalmic adverse reactions and assessment related to immune checkpoint inhibitors and antibody-drug conjugates are at the forefront of research in this field. Adverse drug events and clinical research on drugs may still be the continuous hotspots of future research.

R969.3

天津市眼科医院重点项目（YKZD2005)